April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Quality of life of patients suffering from exudative age-related macular degeneration and treated by intravitreal injections and its predictors: The EQUADE Study.
Author Affiliations & Notes
  • Sahbi Rouissi
    Ophtalmology, Poitiers University Hospital, Poitiers, France
  • Emilie Matmaros
    Ophtalmology, Poitiers University Hospital, Poitiers, France
  • Frederic Maurel
    IMS Health, La Défense, France
  • Marc Joubert
    Association DMLA, Paris, France
  • Martine Hermans
    Retina France Association, Colombiers, France
  • Eric Moser
    Retina France Association, Colombiers, France
  • Serge Le Picard
    Retina France Association, Colombiers, France
  • Rocio Blanco-Gravito
    Creteil Eye University, Creteil, France
  • Eric H Souied
    Creteil Eye University, Creteil, France
  • Nicolas Leveziel
    Ophtalmology, Poitiers University Hospital, Poitiers, France
  • Footnotes
    Commercial Relationships Sahbi Rouissi, None; Emilie Matmaros, None; Frederic Maurel, None; Marc Joubert, None; Martine Hermans, None; Eric Moser, None; Serge Le Picard, None; Rocio Blanco-Gravito, None; Eric Souied, None; Nicolas Leveziel, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 656. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sahbi Rouissi, Emilie Matmaros, Frederic Maurel, Marc Joubert, Martine Hermans, Eric Moser, Serge Le Picard, Rocio Blanco-Gravito, Eric H Souied, Nicolas Leveziel, ; Quality of life of patients suffering from exudative age-related macular degeneration and treated by intravitreal injections and its predictors: The EQUADE Study.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):656.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To assess the quality of life (QoL) of patients with an exudative Age-Related Macular Degeneration (AMD) treated by intravitreal Anti-VEGF (vascular endothelial growth factor) and determine its drivers in a real-life setting.

 
Methods
 

A self-reported survey was carried out among AMD patients belonging to 2 French associations. Only patients with exudative AMD and under active intravitreal anti-VEGF treatment over the last 6 months were included. Data on demographics, disease parameters, past and ongoing treatments were collected. One validated vision-specific QoL instrument was also considered: the NEI-VFQ-25. Patients were stratified into four groups of visual acuity (VA). A multivariate model was performed to identify the QoL drivers.

 
Results
 

Out of the 1,888 questionnaires mailed 32.4% were returned and 24.7% fulfilled the inclusions criteria and were fully completed for analyses. Patients’ mean age was 78.0 years (SD 7.6). 70.5% were women. 60.4% had bilateral disease. The mean duration of symptomatic exudative AMD was respectively of 7.2 (SD 5) and 2.3 years (SD 3) for the 1st and the 2nd eye. Most of anti-VEGF treated eyes (n=641) were treated for more than 1 year (77.4%). The mean annual number of anti-VEGF injections was 4.7 (SD 2.7). The mean NEI-VFQ-25 global score was 53.4 (SD 21.5). A decrease of this score was positively correlated to VA decrease (0.63;p<.0001). This correlation was observed for 11 subscales out of 12. The main risk factor associated to the lower Qol score was the worst VA category, with an odds ratio of 5.2 (CI95%[2.6-10.4];p<.0001).

 
Conclusions
 

In a real-life survey of patients treated and followed for exudative AMD, VA decrease was the strongest factor linked to QoL worsening. Other factors such as the number of Anti-VEGF injections were not correlated to QoL in this study. Then, preservation of useful VA still remains a major concern to improve patients’ QoL.

 
Keywords: 412 age-related macular degeneration • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×